Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec) for the Treatment of Dystrophic Epidermolysis Bullosa
The rendering of the above VYJUVEK™ carton is for illustrative purposes only and is not actual product image